Talecris Biotherapeutics Holdings Corp.
V9SNS*IJTicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at Talecris Biotherapeutics Holdings Corp. (V9SNS*IJ) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 4 insiders have filed 4 transactions totaling $10.9M in trading activity. The most active insider is John R. Perkins II (Executive), contributing $5.3M across 1 transactions.
Talecris Biotherapeutics Holdings Corp. insiders are currently net sellers of V9SNS*IJ stock, showing bearish sentiment over the past 90 days. Total sales of $10.9M outpace purchases of $0, creating a net outflow of $10.9M.
Talecris Biotherapeutics Holdings Corp. has 4 active insiders who have filed SEC Form 4 transactions in the past 90 days. John R. Perkins II (Executive) leads with 1 transactions totaling $5.3M. Thomas J. Lynch (Executive) follows with 1 transactions worth $2.6M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Talecris Biotherapeutics Holdings Corp.'s current score of 0/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.
The most recent insider transaction occurred on Sep 3, 2010, when J. Lynch Thomas (Executive) disposed of 113,440 shares at $22.50 per share for $2.6M. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, V9SNS*IJ insider trading sentiment is currently bearish with an Alignment Score of 0/100. The negative net flow of $10.9M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Talecris Biotherapeutics Holdings Corp.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At V9SNS*IJ, we track all Form 4 filings—currently showing 4 transactions from 4 insiders over 90 days.
A 10b5-1 plan allows Talecris Biotherapeutics Holdings Corp. executives to pre-schedule stock sales when they don't possess material non-public information. At V9SNS*IJ, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at V9SNS*IJ appears discretionary, making insider signals more meaningful.
You can monitor Talecris Biotherapeutics Holdings Corp. (V9SNS*IJ) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 4 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at Talecris Biotherapeutics Holdings Corp. (V9SNS*IJ) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 4 insiders are actively trading V9SNS*IJ stock, having executed 4 transactions in the past 90 days. The most active insider is John R. Perkins II (Executive), with 1 transactions totaling $5.3M.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Talecris Biotherapeutics Holdings Corp.'s current score of 0/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $0 in purchases versus $10.9M in sales over 90 days, resulting in a net flow of -$10.9M.
SEC Form 4 filings are mandatory reports that Talecris Biotherapeutics Holdings Corp. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At V9SNS*IJ, the most common type is "S" with 4 occurrences. The most recent Form 4 was filed on Sep 3, 2010 by J. Lynch Thomas.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Talecris Biotherapeutics Holdings Corp., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at V9SNS*IJ represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for Talecris Biotherapeutics Holdings Corp. and 40,000+ other insiders.